Compare Perspective Therapeutics, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 190 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.71
-33.93%
0.78
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2025)
Net Profit:
-26 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
98.71%
0%
98.71%
6 Months
18.11%
0%
18.11%
1 Year
30.79%
0%
30.79%
2 Years
-46.21%
0%
-46.21%
3 Years
1054.61%
0%
1054.61%
4 Years
22.94%
0%
22.94%
5 Years
-71.24%
0%
-71.24%
Perspective Therapeutics, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-31.24%
EBIT Growth (5y)
-274.73%
EBIT to Interest (avg)
-26.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.03
Tax Ratio
2.42%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
91.28%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.87
EV to EBIT
-0.49
EV to EBITDA
-0.51
EV to Capital Employed
0.49
EV to Sales
25.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-100.05%
ROE (Latest)
-21.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 31 Schemes (32.11%)
Foreign Institutions
Held by 52 Foreign Institutions (4.7%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
0.20
0.30
-33.33%
Operating Profit (PBDIT) excl Other Income
-27.10
-23.30
-16.31%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
-26.00
-22.00
-18.18%
Operating Profit Margin (Excl OI)
-133,306.20%
-82,893.10%
-5,041.31%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -33.33% vs 0.00% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -18.18% vs -20.88% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1.50
1.40
7.14%
Operating Profit (PBDIT) excl Other Income
-64.50
-39.90
-61.65%
Interest
0.00
0.10
-100.00%
Exceptional Items
-24.10
0.00
Consolidate Net Profit
-78.30
-37.50
-108.80%
Operating Profit Margin (Excl OI)
-45,940.20%
-28,550.20%
-1,739.00%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
About Perspective Therapeutics, Inc. 
Perspective Therapeutics, Inc.
Pharmaceuticals & Biotechnology
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.
Company Coordinates 
Company Details
350 Hills St Ste 106 , RICHLAND WA : 99354-5511
Registrar Details






